Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

Summary

This study will recruit 316 ischemic stroke patients taking aspirin. They will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month. The primary outcome variable of this study is rate of biochemical aspirin resistance on the Ultra Rapid Platelet Function Assay-ASA.

Timeline

Start

2007-03

Primary completion

2008-06

Completion

2008-07

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Cilostazol vs Placebo; p = 0.654; Odds Ratio (OR) 0.82; Chi-squared NCT00446641 ↗

Drugs

Indications